LLY vs DXCM
By Alex · Tickerpine
Eli Lilly and Company vs DexCom, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | DXCM |
|---|---|---|
| Price | $1,208.12 | $70.14 |
| Market cap | $1.08T | $27.07B |
| P/E ratio | 42.9 | 30.1 |
| ROE | 107.46% | 35.62% |
| Profit margin | 34.99% | 19.31% |
| Revenue growth | 55.50% | 15.00% |
| Dividend yield | 0.57% | — |
| Beta | 0.52 | 1.44 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs DXCM in plain English
- LLY is the bigger company — about 39.8× the market cap of DXCM.
- DXCM is cheaper on earnings (P/E 30.1 vs 42.9).
- LLY earns a higher return on equity (107% vs 36%).
- LLY is growing revenue faster (56% vs 15%).
- LLY pays a dividend (0.57%) while the other effectively doesn't.
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
DXCM return calculator
See what $1,000 in DexCom, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.